LATEST NEWS

Upcoming Webcast: Interim Results in Pancreatic Cancer

Presentation: AACR – Pancreatic Cancer Interim Data

Presentation: TACTOPS Investor Presentation

STOCK INFORMATION

Marker Therapeutics, Inc.

NSDQ: MRKR

Volume

Day's Range

$

()

Change

52 Week Range

COMPANY OVERVIEW

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. We are advancing two MultiTAA T cell pipelines: our autologous T cells for the treatment of lymphoma, multiple myeloma and selected solid tumors and our allogeneic T cells for the treatment of acute myeloid leukemia, or AML, and acute lymphoblastic leukemia, or ALL. Because we do not genetically engineer our MultiTAA therapies, we believe that our product candidates are easier and less expensive to manufacture, with reduced toxicities, than current engineered CAR-T and T cell receptor-based therapies, and may provide patients with meaningful clinical benefit.

We are also developing innovative peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart, a proprietary nucleic acid-based antigen expression technology designed to improve the ability of the immune system to recognize and destroy diseased cells.

LATEST FINANCIAL RESULTS

Q1 2019

Quarterly Results, March 31, 2019      

10-K Book

LATEST 10-K

IR CONTACT DETAILS

Marker Therapeutics, Inc.

Phoenix Tower
3200 Southwest Fwy #2240
Houston, TX 77027
investor.relations@markertherapeutics.com